Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Amicus Therapeutics (FOLD) over the last 6 years, with Dec 2024 value amounting to $304.4 million.

  • Amicus Therapeutics' Shares Outstanding (Diluted Average) rose 1.88% to $310.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.4 million, marking a year-over-year increase of 1.88%. This contributed to the annual value of $304.4 million for FY2024, which is 3.12% up from last year.
  • As of FY2024, Amicus Therapeutics' Shares Outstanding (Diluted Average) stood at $304.4 million, which was up 3.12% from $295.2 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $304.4 million in FY2024 and a low of $258.9 million during FY2020.
  • For the 3-year period, Amicus Therapeutics' Shares Outstanding (Diluted Average) averaged around $296.2 million, with its median value being $295.2 million (2023).
  • Data for Amicus Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY rose of 7.67% (in 2020) over the last 5 years.
  • Over the past 5 years, Amicus Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $258.9 million in 2020, then increased by 4.85% to $271.4 million in 2021, then climbed by 6.50% to $289.1 million in 2022, then grew by 2.11% to $295.2 million in 2023, then rose by 3.12% to $304.4 million in 2024.